BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
- Conditions
- HIV Infections
- Interventions
- Drug: Atazanavir/ Stavidine / LamivudineDrug: Atazanavir-Ritonavir/ Stavidine / Lamivudine
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00084253
- Locations
- 🇺🇸
Various locations within the US, Call for Information, New Jersey, United States
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- Interventions
- Biological: ipilimumabBiological: Tyrosinase/gp100/MART-1 Peptides
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 77
- Registration Number
- NCT00084656
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
Study of MDX-010 in Stage IV Breast Cancer
- Conditions
- Breast CancerAdenocarcinoma
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT00083278
- Locations
- 🇺🇸
LaGrange, LaGrange, Kentucky, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸Medical Arts Building, Jeffersonville, Indiana, United States
Effectiveness of KOS-862 in the Treatment of Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT00080509
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00017043
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-08-28
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00067782
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
- First Posted Date
- 2003-07-29
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 195
- Registration Number
- NCT00065507
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇬🇷Local institution, Athens, Greece
🇺🇸Mount Sinai Medical Center, New York, New York, United States
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors
- First Posted Date
- 2003-04-03
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00057473
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00024284
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
- Conditions
- Hepatitis B
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00051038
- Locations
- 🇺🇸
Local Institution, Pittsburgh, Pennsylvania, United States